We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hematological Parameters Evaluated for Cervicocranial Arterial Dissection Stroke

By LabMedica International staff writers
Posted on 23 Sep 2020
As artery detachment, artery dissection refers to the vascular disease in which blood flow enters the artery wall and causes dissection of vascular wall. More...
Cervicocranial arterial dissection (CCAD) can lead to stenosis or occlusion of the lumen has become one of the most frequent causes for ischemic stroke in the young.

Patients with CCAD are frequently complicated by coagulopathy and neurological complications, which consisted of permanent neurological dysfunction such as acute ischemic stroke (AIS) and temporary neurological dysfunction such as headache, delirium, or a transient focal neurological deficit.

Neurologists at the First Affiliated Hospital of Soochow University (Suzhou, China) retrospectively analyzed 52 patients with AIS caused by CCAD from emergency room (group I), 51 patients with CCAD from emergency room or clinic (group II) and 52 controls (group III), age and sex matched. Data were collected on the admission including neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR). Blood count analysis was carried out using a Sysmex XS‐500i autoanalyzer (Sysmex Corporation, Kobe, Japan). The serum biochemical parameters were assayed by automatic ADVIA 1800 biochemical analyzer (Siemens Medical Solutions, Malvern, PA, USA).

The scientists reported that the NLR and LMR have significant differences among the three groups, especially in group I versus both groups II and III. There was a negative correlation between admission NLR and LMR. Low LMR level and high NLR level may be associated with severity of AIS caused by CCAD and significantly predict AIS in CCAD. The area under the curve of NLR and LMR were 0.77 and 0.71, respectively, on receiver operating characteristic curve analysis. The optimal cutoff values of NLR and LMR that best discriminated AIS were 2.35 (81% sensitivity and 63% specificity) and 3.67 (64% sensitivity and 77% specificity), respectively.

The authors concluded that NLR and LMR on admission as inflammatory biomarkers which might be useful in the diagnosis of AIS by CCAD. These reliable and easy‐to‐use predictors could contribute to clinical treatment strategy design in patients with CCAD. The study was published on September 7, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
First Affiliated Hospital of Soochow University
Sysmex Corporation
Siemens Medical Solutions



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.